(Q38130610)

29 August 2017

0 references

Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis (English)

1 reference

29 August 2017

0 references

1 reference

1 reference

K C Hourdequin

1

1 reference

29 August 2017

W L Schpero

2

1 reference

29 August 2017

D R McKenna

3

1 reference

29 August 2017

B L Piazik

4

1 reference

29 August 2017

R J Larson

5

1 reference

29 August 2017

21 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

24

1 reference

29 August 2017

12

1 reference

29 August 2017

2952-2962

1 reference

Prevalence and trends in obesity among US adults, 1999-2008

29 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Commentary: chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Obesity and therapy-related toxicity in patients treated for small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

The association of chemotherapy induced neutropenia on treatment outcomes in small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Effect of obesity on survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Dose-response effect of adjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

The influence of relative body weight on toxicity of combination chemotherapy with cisplatin and etoposide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Is dose normalization to weight or body surface area useful in adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Target concentration intervention in oncology: where are we at?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT294

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDT294

1 reference

29 August 2017

1 reference